Publications by authors named "Betzabe Cisternas"
Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study.
Vaccines (Basel)
July 2023
Cancer patients on chemotherapy have a lower immune response to SARS-CoV-2 vaccines. Therefore, through a prospective cohort study of patients with solid tumors receiving chemotherapy, we aimed to determine the immunogenicity of an mRNA vaccine booster (BNT162b2) among patients previously immunized with an inactivated (CoronaVac) or homologous (BNT162b2) SARS-CoV-2 vaccine. The primary outcome was the proportion of patients with anti-SARS-CoV-2 neutralizing antibody (NAb) seropositivity at 8-12 weeks post-booster.
View Article and Find Full Text PDFArticle Synopsis
- Gastric cancer (GC) is a varied disease with differences in forms and regional effects; this study focuses on Chile, which has a high GC mortality rate.
- Researchers studied 224 Chilean patients using tissue microarray and next generation sequencing, finding that 60% had actionable genetic changes, and notable markers for immunotherapy, including a 20.5% high tumor mutational burden and 13% micro-satellite instability (MSI).
- The study identified new genetic variants, confirmed prior findings related to Epstein-Barr virus (EBV), and suggested significant potential for immunotherapy in the Chilean GC patient population, marking a first in South America for such research.
Unlabelled: Gastric cancer (GC) is the world's second-leading cause of neoplastic mortality. Genetic alterations, response to treatments, and mortality rates are highly heterogeneous across different regions. Within Latin America, GC is the leading cause of cancer death in Chile, affecting 17.
View Article and Find Full Text PDF